WHAT IS CLAIMED IS:

1. A compound of Formula I



I

wherein

R^{1a} is independently selected from

1) H,
2) unsubstituted or substituted C_1-C_6 alkyl, and
3) OR^4;

R^{1b} is independently selected from

1) H, and
2) unsubstituted or substituted C_1-C_6 alkyl;

X is independently selected from

1) a bond,
2) C(O),
3) O,
4) NR^4,
5) $S(O)_mR^4$,
6) $C(O)OR^4$, and
7) $C(O)N(R^4)_2$;

R^1 is independently selected from

1) H,
2) halo,
3) OR^4,
4) NO_2,
5) $-S(O)_mR^4$,
6) CN
7) unsubstituted or substituted C_1-C_{10} alkyl,
8) unsubstituted or substituted aryl,
9) unsubstituted or substituted C_2-C_6 alkenyl,
10) unsubstituted or substituted C_3-C_{10} cycloalkyl,
11) unsubstituted or substituted C_2-C_6 alkynyl,
12) unsubstituted or substituted heterocycle,
13) $-C(O)R^4$,
14) $C(O)OR^4$,
15) $C(O)N(R^4)_2$,
16) $S(O)_mN(R^4)_2$, and
17) $N(R^4)_2$;

V is independently selected from

1) H,
2) CF_3,
3) aryl,
4) heterocycle, and
5) C_3-C_{10} cycloalkyl;

R^2 is independently selected from

1) H,
2) unsubstituted or substituted C_1-C_{10} alkyl,

3) $-(CR^{1b})_tOR^4$,
4) Halo,
5) CN,
6) NO_2,
7) CF_3,
8) $-(CR^{1b})_tN(R^4)_2$,
9) $-C(O)OR^4$,
10) $-C(O)R^4$,
11) $-S(O)_2R^4$,
12) $-(CR^{1b})_tNR^4(CR^{1b})_tR^5$,
13) $-(CR^{1b})_tS(O)_mNR^4$,
14) $-C(O)OR^4R^5$,
15) $-NR^4C(O)R^4$,
16) unsubstituted or substituted aryl, and
17) unsubstituted or substituted heterocycle;

R^4 is independently selected from

1) H,
2) unsubstituted or substituted C_1-C_{10} alkyl,
3) unsubstituted or substituted C_3-C_{10} cycloalkyl,
4) unsubstituted or substituted aryl,
5) unsubstituted or substituted heterocycle, and
6) CF_3;

R^5 is independently selected from

1) unsubstituted or substituted aryl, and
2) unsubstituted or substituted heterocycle;

m is independently 0, 1 or 2;

n is 0 to 6;

p is 0 to 6;

q is 0 to 6, provided that when V is H or CF_3, q is 0; and

s is 0 to 16;

t is independently 0 to 6;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to Claim 1, wherein

R^{1b}, R^4, R^5 and variables m, n, p, q and t are as defined in Claim 1 and

R^{1a} is independently selected from

1) H, and

2) unsubstituted or substituted C_1-C_6 alkyl;

X is independently selected from

1) a bond,

2) –C(O)R^4, and

3) C(O);

R^1 is independently selected from

1) H,

2) halo,

3) OR^4,

4) $N(R^4)_2$,

5) NO_2, and

6) unsubstituted or substituted C_1-C_{10} alkyl;

V is independently selected from

1) H,

2) CF_3,

3) aryl, and

4) heterocycle;

R^2 is independently selected from

1) H,

2) unsubstituted or substituted C_1-C_{10} alkyl,

3) $-(CR^{1b})_tOR^4$,

4) Halo,

5) CN,

6) NO_2,

7) CF_3,

8) $-(CR^{1b})_tN(R^4)_2$,

9) $-C(O)OR^4$,

10) $-(CR^{1b})_tS(O)_mNR^4$,

11) $-(CR^{1b})_tNR^4(CR^{1b})_tR^5$,

12) $-C(O)OR^4R^5$, and

13) $-NR^4C(O)R^4$;

s is 0 to 6;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound according to Claim 2 wherein wherein R^{1b}, X, R^1, R^2, R^4, R^5 and variables m, s and t are as defined in Claim 2 and

R^{1a} is independently selected from

1) H, and

2) unsubstituted or substituted C_1-C_6 alkyl;

V is independently selected from
1) aryl, and
2) heterocycle;

n is 0 to 3;
p is 0 to 3;
q is 0 to 3;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. A compound that is
3-(3-bromobenzyl)-11-methyl-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3,11-bis(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

11-acetyl-3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

6. A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

7. The method of Claim 6 wherein the protein kinase is an RTK.

8. The method of Claim 7, wherein the RTK is selected from IR, IGF-1R and IRR.

9. A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

10. A method of Claim 9, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

1) cancer,
2) diabetes,
3) an autoimmune disorder,
4) a hyperproliferation disorder,
5) aging,
6) acromegaly, and
7) Crohn's disease.

11. A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

12. A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compoung of Claim 1.

13. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

1) an estrogen receptor modulator,
2) an androgen receptor modulator,

3) retinoid receptor modulator,
4) a cytotoxic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor, and
10) an angiogenesis inhibitor.

14. The method of Claim 13, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

15. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

16. The method of Claim 15 wherein radiation therapy is also administered.

17. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

18. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

19. The method of Claim 18 wherein the GPIIb/IIIa antagonist is tirofiban.

20. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.